# Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

> **NCT04304209** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 195 (estimated)

## Conditions studied

- Colorectal Cancer Stage II
- Colorectal Cancer Stage III

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Sintilimab
- **RADIATION:** radiotherapy
- **PROCEDURE:** total mesorectal excision
- **OTHER:** Watch and wait

## Key facts

- **NCT ID:** NCT04304209
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-28
- **Primary completion:** 2026-10-18
- **Final completion:** 2026-10-18
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304209, "Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04304209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*